News & Events zu Exagen Inc (XGN)XGNExagen Inc

Company Raises 2026 Revenue Guidance to $72M-$75M

Consensus $71.67M. The company said, "The Company increased full-year 2026 revenue guidance to $72 million - $75 million compared to previous guidance of $70 million - $73 million."

Exagen Reports Q2 Revenue of $19.94M, Beating Consensus

Reports Q2 revenue $19.94M, consensus $17.87M. "We continue to advance Exagen's unique mission to bring clarity to autoimmune disease," said John Aballi, President and Chief Executive Officer. "Second quarter financial results demonstrate the progress we're making in improving the growth and operating profile of our business, putting us within reach of sustainable profitability and cash generation. At the same time, we are building on Exagen's leadership in autoimmune diagnostics through continued investment in clinical evidence generation, pipeline innovation and AI-powered tools that support rheumatology workflows to strengthen our role in rheumatology decision-making."

Spero Therapeutics Appoints Debra Jeske Zack as Chief Medical Officer

Spero Therapeutics (SPRO) announced the appointment of Debra Jeske Zack as chief medical officer. Zack will lead Spero's clinical development strategy and organization as the company advances its immunology program. Most recently, Zack served as chief medical officer of Exagen (XGN).